SURF
Price:
$1.07
Market Cap:
$65.08M
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement ...[Read more]
Industry
Biotechnology
IPO Date
2018-04-19
Stock Exchange
NASDAQ
Ticker
SURF
According to Surface Oncology, Inc.’s latest financial reports and current stock price. The company's current ROE is -113.52%. This represents a change of 253.13% compared to the average of -32.15% of the last 4 quarters.
The mean historical ROE of Surface Oncology, Inc. over the last ten years is -5.45%. The current -113.52% ROE has changed 1.98% with respect to the historical average. Over the past ten years (40 quarters), SURF's ROE was at its highest in in the March 2018 quarter at 113.30%. The ROE was at its lowest in in the June 2023 quarter at -57.33%.
Average
-5.45%
Median
-66.83%
Minimum
-93.54%
Maximum
241.41%
Discovering the peaks and valleys of Surface Oncology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.36%
Maximum Annual ROE = 241.41%
Minimum Annual Increase = -398.28%
Minimum Annual ROE = -93.54%
Year | ROE | Change |
---|---|---|
2022 | -69.92% | 4.62% |
2021 | -66.83% | -275.42% |
2020 | 38.10% | -140.73% |
2019 | -93.54% | 1.36% |
2018 | -6.41% | -102.66% |
2017 | 241.41% | -398.28% |
The current ROE of Surface Oncology, Inc. (SURF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-32.88%
5-year avg
-39.72%
10-year avg
-5.45%
Surface Oncology, Inc.’s ROE is greater than Syros Pharmaceuticals, Inc. (-853.34%), greater than Repare Therapeutics Inc. (-31.11%), greater than Personalis, Inc. (-63.43%), greater than Evogene Ltd. (-189.58%), greater than Iovance Biotherapeutics, Inc. (-65.04%),
Company | ROE | Market cap |
---|---|---|
-853.34% | $40.49M | |
-31.11% | $119.70M | |
-63.43% | $285.67M | |
-189.58% | $14.97M | |
-65.04% | $3.04B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Surface Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Surface Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Surface Oncology, Inc.'s ROE?
How is the ROE calculated for Surface Oncology, Inc. (SURF)?
What is the highest ROE for Surface Oncology, Inc. (SURF)?
What is the 3-year average ROE for Surface Oncology, Inc. (SURF)?
What is the 5-year average ROE for Surface Oncology, Inc. (SURF)?
How does the current ROE for Surface Oncology, Inc. (SURF) compare to its historical average?